Trials / Terminated
TerminatedNCT05629208
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
A Randomized, Blinded, Placebo-Controlled, Phase 2a, Proof-of-Concept Study to Evaluate Efficacy, Safety, and Tolerability of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Edecesertib | Tablets administered orally |
| DRUG | Edecesertib Placebo | Tablets administered orally |
Timeline
- Start date
- 2023-04-17
- Primary completion
- 2025-12-17
- Completion
- 2026-01-14
- First posted
- 2022-11-29
- Last updated
- 2026-02-17
Locations
17 sites across 3 countries: United States, Germany, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05629208. Inclusion in this directory is not an endorsement.